Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

scientific article published on 6 December 2014

Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/IJC.29386
P932PMC publication ID4458227
P698PubMed publication ID25482078

P50authorJan LubińskiQ11718282
Pål MøllerQ29643284
Susan L NeuhausenQ63019538
Jeffrey N WeitzelQ63032640
Leigha SenterQ63370944
Joanne KotsopoulosQ89542094
Nadine M TungQ90166331
Jacek GronwaldQ91084015
Beth KarlanQ95982319
Charmaine Kim-SingQ114456214
Hereditary Breast Cancer Clinical Study GroupQ114456216
Rochelle DemskyQ114456265
Cezary CybulskiQ42590472
Steven A. NarodQ50384888
P2093author name stringPing Sun
Susan Friedman
P2860cites workAverage risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studiesQ24531993
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage ConsortiumQ29619206
Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controlsQ31147531
A candidate precursor to serous carcinoma that originates in the distal fallopian tube.Q33264156
Risk factors for epithelial ovarian cancer by histologic subtypeQ33552610
Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutationQ33633402
Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysisQ33845209
Incessant ovulation--a factor in ovarian neoplasia?Q34051579
Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutationsQ53100748
Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?Q53438901
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndromeQ53639283
Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control studyQ57908386
Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis?Q77415599
Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesteroneQ77636062
Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States)Q78602227
Timing of pregnancy and the risk of epithelial ovarian cancerQ78830120
Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from PolandQ81425159
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancerQ34113283
Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysisQ34120135
Lactational control of reproductionQ34127480
Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis.Q34216239
Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysisQ34379186
Maternal recall of breastfeeding duration twenty years after deliveryQ34486984
The Epidemiology of Endometrial and Ovarian CancerQ35676052
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Q35737888
Endogenous hormones and ovarian cancer: epidemiology and current hypotheses.Q36019178
Long-Term Ovarian Cancer Survival Associated With Mutation in BRCA1 or BRCA2Q36727459
Reproductive characteristics in relation to ovarian cancer risk by histologic pathwaysQ36768628
Early events in the pathogenesis of epithelial ovarian cancerQ37057044
Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspectiveQ37094004
Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer preventionQ37125079
Hormonal risk factors for ovarian cancer in premenopausal and postmenopausal womenQ37145818
Ovulation and ovarian cancerQ37170501
Precursors to pelvic serous carcinoma and their clinical implicationsQ37399709
Refractory fallopian tube carcinoma - current perspectives in pathogenesis and managementQ37553978
Reproducibility of oral contraceptive histories and validity of hormone composition reported in a cohort of US womenQ38503066
"Incessant ovulation" and ovarian cancerQ39559428
Parity, age at first childbirth, and risk of ovarian cancerQ43706332
Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriersQ44256039
Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort StudyQ44884896
Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancerQ45050625
Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriersQ51644200
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriersQ51842388
Medical record validation of maternally reported birth characteristics and pregnancy-related events: a report from the Children's Cancer GroupQ52005567
P433issue5
P407language of work or nameEnglishQ1860
P921main subjectovarian cancerQ172341
BRCA1 MutationQ28444960
P304page(s)1136-1146
P577publication date2014-12-06
P1433published inInternational Journal of CancerQ332492
P1476titleFactors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
P478volume137

Reverse relations

cites work (P2860)
Q37190034Age related increase in mTOR activity contributes to the pathological changes in ovarian surface epithelium
Q88791860Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation
Q94221905Association of Combined Estrogen–Progestogen and Progestogen-Only Contraceptives with the Development of Cancer
Q37330894BNC2 is a putative tumor suppressor gene in high-grade serous ovarian carcinoma and impacts cell survival after oxidative stress
Q100430759Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation
Q47228795Dietary inflammatory index and ovarian cancer risk in a New Jersey case-control study.
Q47554393Fertility preservation in BRCA-mutated women: when and how?
Q39370774Germline Mutations in Triple-Negative Breast Cancer
Q44637964Let-7d increases ovarian cancer cell sensitivity to a genistein analog by targeting c-Myc
Q57988152Menopausal hormone therapy—ovarian cancer risk revisited
Q60946525Mutations and Breast Cancer Prevention
Q96022585Ovarian BDNF promotes survival, migration, and attachment of tumor precursors originated from p53 mutant fallopian tube epithelial cells
Q37662145Ovarian hormones through Wnt signalling regulate the growth of human and mouse ovarian cancer initiating lesions
Q57453316Personalised medicine and population health: breast and ovarian cancer
Q57137351Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect
Q26780387Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Q40287145Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
Q89879980Screening and Prevention for High-Grade Serous Carcinoma of the Ovary Based on Carcinogenesis-Fallopian Tube- and Ovarian-Derived Tumors and Incessant Retrograde Bleeding
Q90614419Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study

Search more.